{"id":"NCT03345979","sponsor":"Alkermes, Inc.","briefTitle":"A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia","officialTitle":"A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-15","primaryCompletion":"2019-03-12","completion":"2019-03-12","firstPosted":"2017-11-17","resultsPosted":"2020-08-11","lastUpdate":"2020-08-11"},"enrollment":200,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Aripiprazole Lauroxil","otherNames":["ARISTADA","ARISTADA INITIO"]},{"type":"DRUG","name":"Paliperidone Palmitate","otherNames":["Invega Sustenna"]}],"arms":[{"label":"Treatment Group 1","type":"EXPERIMENTAL"},{"label":"Treatment Group 2","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.","primaryOutcome":{"measure":"Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4","timeFrame":"Baseline and 4 weeks","effectByArm":[{"arm":"Aripiprazole Lauroxil","deltaMin":-17.4,"sd":11.57},{"arm":"Paliperidone Palmitate","deltaMin":-20.1,"sd":13.72}],"pValues":[{"comp":"OG000","p":"<.001"},{"comp":"OG001","p":"<.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":7},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":["39145678","38416865","34625041","32433835"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":99},"commonTop":["Injection Site Pain","Weight increased","Akathisia","Headache","Somnolence"]}}